|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 27461 |
FusionGeneSummary for PLAT_SUPT16H |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: PLAT_SUPT16H | Fusion gene ID: 27461 | Hgene | Tgene | Gene symbol | PLAT | SUPT16H | Gene ID | 5327 | 11198 |
| Gene name | plasminogen activator, tissue type | SPT16 homolog, facilitates chromatin remodeling subunit | |
| Synonyms | T-PA|TPA | CDC68|FACTP140|SPT16|SPT16/CDC68 | |
| Cytomap | 8p11.21 | 14q11.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | tissue-type plasminogen activatoralteplaseplasminogen/activator kringlereteplaset-plasminogen activator | FACT complex subunit SPT16FACT 140 kDa subunitchromatin-specific transcription elongation factor 140 kDa subunitfacilitates chromatin remodeling 140 kDa subunitfacilitates chromatin transcription complex subunit SPT16hSPT16suppressor of Ty 16 homolo | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | P00750 | Q9Y5B9 | |
| Ensembl transtripts involved in fusion gene | ENST00000270189, ENST00000429089, ENST00000220809, ENST00000352041, ENST00000519510, ENST00000429710, ENST00000524009, | ENST00000216297, ENST00000555943, | |
| Fusion gene scores | * DoF score | 3 X 2 X 2=12 | 37 X 4 X 15=2220 |
| # samples | 4 | 40 | |
| ** MAII score | log2(4/12*10)=1.73696559416621 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(40/2220*10)=-2.47248777146274 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: PLAT [Title/Abstract] AND SUPT16H [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | PLAT | GO:0031639 | plasminogen activation | 12694198|17849409|24196407 |
| Hgene | PLAT | GO:0045861 | negative regulation of proteolysis | 1695900 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | HNSC | TCGA-DQ-7589-01A | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-intron | ENST00000270189 | ENST00000216297 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| intron-intron | ENST00000270189 | ENST00000555943 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| 5CDS-intron | ENST00000429089 | ENST00000216297 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| 5CDS-intron | ENST00000429089 | ENST00000555943 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| 5CDS-intron | ENST00000220809 | ENST00000216297 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| 5CDS-intron | ENST00000220809 | ENST00000555943 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| 5CDS-intron | ENST00000352041 | ENST00000216297 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| 5CDS-intron | ENST00000352041 | ENST00000555943 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| intron-intron | ENST00000519510 | ENST00000216297 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| intron-intron | ENST00000519510 | ENST00000555943 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| intron-intron | ENST00000429710 | ENST00000216297 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| intron-intron | ENST00000429710 | ENST00000555943 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| intron-intron | ENST00000524009 | ENST00000216297 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
| intron-intron | ENST00000524009 | ENST00000555943 | PLAT | chr8 | 42032755 | - | SUPT16H | chr14 | 21829491 | - |
Top |
FusionProtFeatures for PLAT_SUPT16H |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| PLAT | SUPT16H |
| Component of the FACT complex, a general chromatinfactor that acts to reorganize nucleosomes. The FACT complex isinvolved in multiple processes that require DNA as a template suchas mRNA elongation, DNA replication and DNA repair. Duringtranscription elongation the FACT complex acts as a histonechaperone that both destabilizes and restores nucleosomalstructure. It facilitates the passage of RNA polymerase II andtranscription by promoting the dissociation of one histone H2A-H2Bdimer from the nucleosome, then subsequently promotes thereestablishment of the nucleosome following the passage of RNApolymerase II. The FACT complex is probably also involved inphosphorylation of 'Ser-392' of p53/TP53 via its association withCK2 (casein kinase II). {ECO:0000269|PubMed:10912001,ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:12934006,ECO:0000269|PubMed:16713563, ECO:0000269|PubMed:9489704,ECO:0000269|PubMed:9836642}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for PLAT_SUPT16H |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for PLAT_SUPT16H |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| PLAT | CLEC3B, CALR, PLAU, KRT8, ANXA2, SERPINI1, SERPINA5, F2, SERPINE1, FGA, LRP1, HMGB1, F10, FN1, LAMA1, TERF2, POT1, PDGFC, FGL1, DCN, TMEM25, PTPRK, IFNA14, LAMA3, SERPINB2, SERPING1, SERPINA10, PLA2G10, SERPINB6, SERPINE2, IGFBP1, DEFA1 | SUPT16H | BRCC3, PRKAA1, POLR1A, POLR1E, SSRP1, CHD1L, MCM4, PAF1, PARP1, H2AFX, MKL1, H3F3A, TRIM33, TAL1, CDK9, SUPT16H, MMS22L, TONSL, SMARCAD1, SREK1, SOX2, HDGF, ELAVL1, XRCC5, CUL3, CDK2, CAND1, FYTTD1, CSNK2A1, CSNK2B, SAP18, RTF1, LEO1, TOP1, DHX15, CTR9, IK, PRPF4B, SNRPD2, NCSTN, S100A9, HNRNPM, NHP2L1, DDX21, PRPF6, SF3A1, SNRPD1, PRPF3, ACIN1, EEF1A1, RBM25, MSH6, PRPF8, USP39, MSH2, PSIP1, CENPA, ESR1, FMNL1, VCP, PNKP, CD81, IGSF8, ICAM1, SRPK2, FTH1, QRICH1, RNF20, ATRX, HIST1H2AB, MOV10, NXF1, BRCA1, CUL7, OBSL1, EED, RNF2, BMI1, SUMO2, ABCE1, RPA4, SPIN2B, RPA2, SPIN1, TIPIN, RNF146, POLB, APLF, HIST1H2BA, MAFF, FBXW11, BRD3, CDK12, HMGB1, IWS1, NAP1L1, PES1, SRRM1, CDK11A, HMGB2, HMGB3, KRI1, TOP2B, ZC3H18, SFN, NTRK1, IFI16, MED4, EWSR1, CEP97, CNTROB, SPICE1, CEP164, DCTN1, POC1B, STIL, HIST1H3E, DAXX, HNRNPU, NPM1, RPL10, ETAA1, CENPQ, NF2, NANOG, UBR5, SBF1, HIST1H3A, MACROD1, H2AFY2, XPC, XRCC6, HIST1H4A, NAA40, WDR76, ALX3, TEAD2, L3MBTL1, CETN1, SIX2, POLL, RPA3, WRN, COX15, DLD, PDHA1, VDAC1, TRIM25, YAP1, MTF1 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for PLAT_SUPT16H |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | PLAT | P00750 | DB01050 | Ibuprofen | Tissue-type plasminogen activator | small molecule | approved |
| Hgene | PLAT | P00750 | DB06404 | Human C1-esterase inhibitor | Tissue-type plasminogen activator | biotech | approved |
| Hgene | PLAT | P00750 | DB00513 | Aminocaproic Acid | Tissue-type plasminogen activator | small molecule | approved|investigational |
| Hgene | PLAT | P00750 | DB01088 | Iloprost | Tissue-type plasminogen activator | small molecule | approved|investigational |
| Hgene | PLAT | P00750 | DB09213 | Dexibuprofen | Tissue-type plasminogen activator | small molecule | approved|investigational |
| Hgene | PLAT | P00750 | DB09228 | Conestat alfa | Tissue-type plasminogen activator | biotech | approved|investigational |
| Hgene | PLAT | P00750 | DB00013 | Urokinase | Tissue-type plasminogen activator | biotech | approved|investigational|withdrawn |
Top |
RelatedDiseases for PLAT_SUPT16H |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | PLAT | C0038454 | Cerebrovascular accident | 59 | CTD_human |
| Hgene | PLAT | C0027051 | Myocardial Infarction | 35 | CTD_human |
| Hgene | PLAT | C0007786 | Brain Ischemia | 25 | CTD_human |
| Hgene | PLAT | C2937358 | Cerebral Hemorrhage | 21 | CTD_human |
| Hgene | PLAT | C0151699 | Intracranial Hemorrhages | 14 | CTD_human |
| Hgene | PLAT | C0034065 | Pulmonary Embolism | 9 | CTD_human |
| Hgene | PLAT | C0019080 | Hemorrhage | 8 | CTD_human |
| Hgene | PLAT | C0007785 | Cerebral Infarction | 6 | CTD_human |
| Hgene | PLAT | C0040053 | Thrombosis | 4 | CTD_human |
| Hgene | PLAT | C0740392 | Infarction, Middle Cerebral Artery | 4 | CTD_human |
| Hgene | PLAT | C0002994 | Angioedema | 3 | CTD_human |
| Hgene | PLAT | C0010072 | Coronary Thrombosis | 3 | CTD_human |
| Hgene | PLAT | C0042487 | Venous Thrombosis | 3 | CTD_human |
| Hgene | PLAT | C0007781 | Intracranial Embolism and Thrombosis | 2 | CTD_human |
| Hgene | PLAT | C0877172 | Hematoma, Epidural, Spinal | 2 | CTD_human |
| Hgene | PLAT | C0001125 | Acidosis, Lactic | 1 | CTD_human |
| Hgene | PLAT | C0001883 | Airway Obstruction | 1 | CTD_human |
| Hgene | PLAT | C0003537 | Aphasia | 1 | CTD_human |
| Hgene | PLAT | C0003838 | Arterial Occlusive Diseases | 1 | CTD_human |
| Hgene | PLAT | C0004153 | Atherosclerosis | 1 | CTD_human |
| Hgene | PLAT | C0004604 | Back Pain | 1 | CTD_human |
| Hgene | PLAT | C0004610 | Bacteremia | 1 | CTD_human |
| Hgene | PLAT | C0007177 | Cardiac Tamponade | 1 | CTD_human |
| Hgene | PLAT | C0013922 | Embolism | 1 | CTD_human |
| Hgene | PLAT | C0018801 | Heart failure | 1 | CTD_human |
| Hgene | PLAT | C0018946 | Hematoma, Subdural | 1 | CTD_human |
| Hgene | PLAT | C0020538 | Hypertensive disease | 1 | CTD_human |
| Hgene | PLAT | C0020649 | Hypotension | 1 | CTD_human |
| Hgene | PLAT | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Hgene | PLAT | C0024031 | Low Back Pain | 1 | CTD_human |
| Hgene | PLAT | C0025309 | Meningoencephalitis | 1 | CTD_human |
| Hgene | PLAT | C0027746 | Nerve Degeneration | 1 | CTD_human |
| Hgene | PLAT | C0030552 | Paresis | 1 | CTD_human |
| Hgene | PLAT | C0031039 | Pericardial effusion | 1 | CTD_human |
| Hgene | PLAT | C0033975 | Psychotic Disorders | 1 | PSYGENET |
| Hgene | PLAT | C0035126 | Reperfusion Injury | 1 | CTD_human |
| Hgene | PLAT | C0035229 | Respiratory Insufficiency | 1 | CTD_human |
| Hgene | PLAT | C0036341 | Schizophrenia | 1 | PSYGENET |
| Hgene | PLAT | C0036980 | Shock, Cardiogenic | 1 | CTD_human |
| Hgene | PLAT | C0037926 | Compression of spinal cord | 1 | CTD_human |
| Hgene | PLAT | C0040038 | Thromboembolism | 1 | CTD_human |
| Hgene | PLAT | C0085307 | Embolism and Thrombosis | 1 | CTD_human |
| Hgene | PLAT | C0149649 | Cholesterol Embolism | 1 | CTD_human |
| Hgene | PLAT | C0162820 | Dermatitis, Allergic Contact | 1 | CTD_human |
| Hgene | PLAT | C0235032 | Neurotoxicity Syndromes | 1 | CTD_human |
| Hgene | PLAT | C0236733 | Amphetamine-Related Disorders | 1 | CTD_human |
| Hgene | PLAT | C0242184 | Hypoxia | 1 | CTD_human |
| Hgene | PLAT | C0242698 | Ventricular Dysfunction, Left | 1 | CTD_human |
| Hgene | PLAT | C0349204 | Nonorganic psychosis | 1 | PSYGENET |
| Hgene | PLAT | C0740858 | Substance abuse problem | 1 | PSYGENET |
| Hgene | PLAT | C0751895 | Vasospasm, Intracranial | 1 | CTD_human |
| Hgene | PLAT | C0751955 | Brain Infarction | 1 | CTD_human |
| Hgene | PLAT | C0752143 | Intracranial Thrombosis | 1 | CTD_human |
| Hgene | PLAT | C1861172 | Venous Thromboembolism | 1 | CTD_human |
| Hgene | PLAT | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|